Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer.

Hisham K DabbousYosry Abd El-Rahman MohamedRunia F El-FollyMohamed D El-TalkawyHani E SeddikDina JoharMohammed A Sarhan

Published in: Journal of gastrointestinal cancer (2020)

Fecal M2PK can be used as a precolonoscopy screening test for CRC patients, and is superior to other tumor markers, and in indicating the progress of colorectal adenomas > 1 cm. Thus being cost-effective and easy-to-perform test, it is a feasible tool to preselect patients who require colonoscopy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
colorectal cancer screening